Anna Klucnika
Stem Cell Gene editing Team Leader
Laverock Therapeutics, United Kingdom
Anna Klucnika is a molecular biologist, currently researching cutting-edge gene editing technologies to accelerate wider implementation of cell therapies and their subsequent tangible benefits for patients.Anna completed her PhD in 2022 at the University of Cambridge, in which she studied mitochondrial genome repair and editing. After her PhD, Anna has continued her research at Laverock Therapeutics, where she leads the iPSC and gene editing team. Laverock Therapeutics is a gene silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of more effective, safer and accessible programmable advanced therapies to tackle major diseases.